BioCentury | Aug 14, 2019
Company News

Patient access, antisense oligo key to Angelman deal for Ultragenyx

...link to patients. The companies teamed up to advance GeneTX Biotherapeutics LLC's preclinical antisense oligonucleotide, GTX-102...
...Ultragenyx's expertise in drug development for rare diseases made it an ideal partner to bring GTX-102...
...development, loss of the maternal allele stops all protein production and results in disease symptoms. GTX-102...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

...GTx Inc. (NASDAQ:GTXI) and Oncternal said the merger will combine Oncternal’s clinical stage oncology pipeline with GTx’s...
...MCL). It is a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1). GTx...
...enobosarm (GTx-024), failed in the Phase II ASTRID trial to treat stress urinary incontinence (see "GTX...
BioCentury | Sep 28, 2018
Clinical News

GTx's enobosarm fails Phase II for stress urinary incontinence

...GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat...
...in that indication, citing changes in the treatment landscape. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Enobosarm (GTx-024...
...day from baseline to week 12 Status: Phase II data Milestone: NA Paul Bonanos Ostarine, enobosarm (GTx-024, mk-2866) GTx Inc. Androgen...
BioCentury | Sep 21, 2018
Clinical News

GTx shares crater after incontinence readout

...cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024...
...3 mg vs. 52.7% for placebo). Enobosarm is a non-steroidal selective androgen receptor modulator (SARM). GTx...
...Capital, Amzak Health, Aisling Capital, Boxer Capital of Tavistock Group and Abingworth. Paul Bonanos Ostarine, enobosarm (GTx-024, mk-2866) GTx Inc....
BioCentury | Aug 10, 2018
Finance

Missing the obvious

...involved in investments for companies and treatments that focus on women’s health. Companies such as GTX Inc....
...performed to alleviate stress urinary incontinence, and there is significant morbidity associated with this procedure. GTX...
...specializing in clinical stage companies. Companies and Institutions Mentioned Biotechnology Innovation Organization (BIO), Washington, D.C. GTx Inc....
BioCentury | Mar 9, 2018
Clinical News

GTx reports additional Phase II stress urinary incontinence data for enobosarm

...18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024...
...presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction meeting in Austin. GTx...
...about 400 postmenopausal women with stress urinary incontinence. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Ostarine enobosarm (GTx-024...
BioCentury | Mar 5, 2018
Clinical News

GTx rises on stress urinary incontinence data

...18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024...
...II ASTRID trial of enobosarm in about 400 postmenopausal women with stress urinary incontinence. Jaime De Leon enobosarm GTx-024 Ostarine GTx Inc. Androgen...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Cancer

...androgen receptor splice variant, the SARD decreased tumor volume compared with vehicle. Next steps by GTx Inc....
...in additional animal models of CRPC (see "Degrade and Destroy." BioCentury Innovations (May 7, 2015)). GTx...
...Androgen receptor; androgen receptor splice variant 7 (AR-V7) LICENSING STATUS: Patent application filed; licensed to GTx Inc....
BioCentury | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...to severe vaginal pain during sexual intercourse associated with vulvar vaginal atrophy due to menopause. GTx Inc....
...to use funds primarily for clinical development of enobosarm (GTx-024) to treat stress urinary incontinence. GTx...
...Fla. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Jennie Walters enobosarm GTx-024 KD025 sarizotan Selective androgen receptor modulator tesevatinib TX-004HR XL647 Aisling Capital GTx Inc. Kadmon...
BioCentury | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...to severe vaginal pain during sexual intercourse associated with vulvar vaginal atrophy due to menopause. GTx Inc....
...to use funds primarily for clinical development of enobosarm (GTx-024) to treat stress urinary incontinence. GTx...
...13%) to $5.28, and Newron slipped CHF1.55 (10%) to CHF14.35. GTx added $0.01 to $8.78. Jennie Walters EMD-128130 estradiol/progesterone Evenamide NW-3509 sarizotan tesevatinib TX-001HR TX-004HR Yuvvexy GTx Inc. Kadmon...
Items per page:
1 - 10 of 322
BioCentury | Aug 14, 2019
Company News

Patient access, antisense oligo key to Angelman deal for Ultragenyx

...link to patients. The companies teamed up to advance GeneTX Biotherapeutics LLC's preclinical antisense oligonucleotide, GTX-102...
...Ultragenyx's expertise in drug development for rare diseases made it an ideal partner to bring GTX-102...
...development, loss of the maternal allele stops all protein production and results in disease symptoms. GTX-102...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

...GTx Inc. (NASDAQ:GTXI) and Oncternal said the merger will combine Oncternal’s clinical stage oncology pipeline with GTx’s...
...MCL). It is a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1). GTx...
...enobosarm (GTx-024), failed in the Phase II ASTRID trial to treat stress urinary incontinence (see "GTX...
BioCentury | Sep 28, 2018
Clinical News

GTx's enobosarm fails Phase II for stress urinary incontinence

...GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat...
...in that indication, citing changes in the treatment landscape. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Enobosarm (GTx-024...
...day from baseline to week 12 Status: Phase II data Milestone: NA Paul Bonanos Ostarine, enobosarm (GTx-024, mk-2866) GTx Inc. Androgen...
BioCentury | Sep 21, 2018
Clinical News

GTx shares crater after incontinence readout

...cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024...
...3 mg vs. 52.7% for placebo). Enobosarm is a non-steroidal selective androgen receptor modulator (SARM). GTx...
...Capital, Amzak Health, Aisling Capital, Boxer Capital of Tavistock Group and Abingworth. Paul Bonanos Ostarine, enobosarm (GTx-024, mk-2866) GTx Inc....
BioCentury | Aug 10, 2018
Finance

Missing the obvious

...involved in investments for companies and treatments that focus on women’s health. Companies such as GTX Inc....
...performed to alleviate stress urinary incontinence, and there is significant morbidity associated with this procedure. GTX...
...specializing in clinical stage companies. Companies and Institutions Mentioned Biotechnology Innovation Organization (BIO), Washington, D.C. GTx Inc....
BioCentury | Mar 9, 2018
Clinical News

GTx reports additional Phase II stress urinary incontinence data for enobosarm

...18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024...
...presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction meeting in Austin. GTx...
...about 400 postmenopausal women with stress urinary incontinence. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Ostarine enobosarm (GTx-024...
BioCentury | Mar 5, 2018
Clinical News

GTx rises on stress urinary incontinence data

...18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024...
...II ASTRID trial of enobosarm in about 400 postmenopausal women with stress urinary incontinence. Jaime De Leon enobosarm GTx-024 Ostarine GTx Inc. Androgen...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Cancer

...androgen receptor splice variant, the SARD decreased tumor volume compared with vehicle. Next steps by GTx Inc....
...in additional animal models of CRPC (see "Degrade and Destroy." BioCentury Innovations (May 7, 2015)). GTx...
...Androgen receptor; androgen receptor splice variant 7 (AR-V7) LICENSING STATUS: Patent application filed; licensed to GTx Inc....
BioCentury | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...to severe vaginal pain during sexual intercourse associated with vulvar vaginal atrophy due to menopause. GTx Inc....
...to use funds primarily for clinical development of enobosarm (GTx-024) to treat stress urinary incontinence. GTx...
...Fla. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Jennie Walters enobosarm GTx-024 KD025 sarizotan Selective androgen receptor modulator tesevatinib TX-004HR XL647 Aisling Capital GTx Inc. Kadmon...
BioCentury | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...to severe vaginal pain during sexual intercourse associated with vulvar vaginal atrophy due to menopause. GTx Inc....
...to use funds primarily for clinical development of enobosarm (GTx-024) to treat stress urinary incontinence. GTx...
...13%) to $5.28, and Newron slipped CHF1.55 (10%) to CHF14.35. GTx added $0.01 to $8.78. Jennie Walters EMD-128130 estradiol/progesterone Evenamide NW-3509 sarizotan tesevatinib TX-001HR TX-004HR Yuvvexy GTx Inc. Kadmon...
Items per page:
1 - 10 of 322